LB Pharmaceuticals: Targeting a Multibillion-Dollar Market – How a Modified Drug Could Transform Psychiatry
Reading Time: 3 minutes
LB Pharmaceuticals (LBRX) is pursuing a new therapeutic approach. LB-102 addresses schizophrenia and other disorders by optimizing an established antipsychotic with fewer side effects. Needham set a high price target of $68 on October 2, supported by an estimated revenue potential of $2.9 billion by 2035. The company expects to release preliminary Phase 3 data in the first half of 2027 and is systematically expanding its clinical pipeline. Business Model and Addressing Global Growth Trends The business model of LB Pharmaceuticals (LBRX)...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
